The combination of lomustine and temozolomide has been proven to be beneficial over temozolomide in patients with MGMT promotor methylated glioblastoma in the NOA-09/CETEG trial [35] and is currently evaluated in patients with 1p/19q codeletion. This evidence concerns the gene MGMT and glioblastoma.